oncotomskСибирский онкологический журналSiberian journal of oncology1814-48612312-3168Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences10.21294/1814-4861-2020-19-6-28-37oncotomsk-1637Research ArticleКЛИНИЧЕСКИЕ ИССЛЕДОВАНИЯCLINICAL STUDIESКЛИНИЧЕСКАЯ ЗНАЧИМОСТЬ ПРОСТАТИЧЕСКОГО СПЕЦИФИЧЕСКОГО АНТИГЕНА У БОЛЬНЫХ РАКОМ МОЛОЧНОЙ ЖЕЛЕЗЫCLINICAL SIGNIFICANSE OF PROSTATE-SPECIFIC ANTIGEN IN BREAST CANCER PATIENTShttps://orcid.org/0000-0001-7406-9973СергееваН. С.SergeevaN. S.

доктор биологических наук, профессор, заведующая отделением прогноза  эффективности консервативного лечения; профессор кафедры биологии педиатрического факультета

SPIN-код: 1805-8141. Author ID (Scopus): 7102748586

Россия, 125284, г. Москва, 2-й Боткинский пр., 3 Россия, 117997, г. Москва, ул. Островитянова, 1

DSc, Professor, Head of the Department of Efficiency of Conservative Therapy Prognosis; Professor of Biology Department

Author ID (Scopus): 7102748586

3, 2nd Botkinskiy proezd, 125284, moscow, Russia

1, ostrovityanova street, 117997, moscow, Russia

prognoz.01@mail.ruhttps://orcid.org/0000-0002-8017-5657КармаковаТ. А.KarmakovaT. A.

доктор биологических наук, ведущий научный сотрудник отделения прогноза эффективности консервативного лечения

SPIN-код: 4364-6134. Author ID (Scopus): 6603382243

Россия, 125284, г. Москва, 2-й Боткинский пр., 3

DSc, Leading Researcher, Department of Efficiency of Conservative Therapy Prognosis

Author ID (Scopus): 6603382243

3, 2nd Botkinskiy proezd, 125284, moscow, Russia

https://orcid.org/0000-0002-5920-5823АлентовИ. И.AlentovI. I.

кандидат биологических наук, научный сотрудник отделения прогноза эффективности консервативного лечения

SPIN-код: 9992-7676

Россия, 125284, г. Москва, 2-й Боткинский пр., 3

PhD, Researcher, Department of Efficiency of Conservative Therapy Prognosis

3, 2nd Botkinskiy proezd, 125284, moscow, Russia

igoralentov@yandex.ruhttps://orcid.org/0000-0001-7141-2502ЗикиряходжаевА. Д.ZikiryahodzhaevA. D.

доктор медицинских наук, профессор кафедры онкологии и рентгенорадиологииРУДН, руководитель отделения онкологии и реконструктивно-пластической хирургии молочной железы и кожи

SPIN-код: 8421-0364. AuthorID (РИНЦ): 701248

Россия, 125284, г. Москва, 2-й Боткинский пр., 3

MD, DSc, Professor, Head of the Department of Oncology and Reconstructive Surgery of Breast and Skin; professor of department of oncology and X-ray radiology of RUDN University

3, 2nd Botkinskiy proezd, 125284, moscow, Russia

ОртабаеваД. Р.OrtabaevaD. R.

хирург, врач-онколог общеклинического отдела

Researcher ID (WOS): Y-6369-2018

Россия, 125284, г. Москва, 2-й Боткинский пр., 3

MD, Surgeon, Oncologist, General Clinic Department

Researcher ID (WOS): Y-6369-2018

3, 2nd Botkinskiy proezd, 125284, moscow, Russia

https://orcid.org/0000-0001-8784-8415КапринА. Д.KaprinA. D.

доктор медицинских наук, профессор, академик РАН, директор 

SPIN-код: 1759-8101. Author ID (Scopus): 6602709853Россия, 125284, г. Москва, 2-й Боткинский пр., 3

MD, DSc, Professor, Member of the Russian Academy of Sciences, Head

Author ID (Scopus): 6602709853

3, 2nd Botkinskiy proezd, 125284, moscow, Russia

МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России; ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава РоссииРоссияP.А. Hertsen Moscow Oncology Research Institute – branch of Federal Medical Research Centre of Radiology; Pirogov Russian National Research Medical UniversityRussian FederationМНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава РоссииРоссияP.А. Hertsen Moscow Oncology Research Institute – branch of Federal Medical Research Centre of RadiologyRussian Federation2020281220201962837Copyright © Сергеева Н.С., Кармакова Т.А., Алентов И.И., Зикиряходжаев А.Д., Ортабаева Д.Р., Каприн А.Д., 20202020Сергеева Н.С., Кармакова Т.А., Алентов И.И., Зикиряходжаев А.Д., Ортабаева Д.Р., Каприн А.Д.Sergeeva N.S., Karmakova T.A., Alentov I.I., Zikiryahodzhaev A.D., Ortabaeva D.R., Kaprin A.D.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.siboncoj.ru/jour/article/view/1637

Простатический специфический антиген (ПСА) преимущественно продуцируется клетками предстательной железы, однако его минорными источниками могут служить и другие ткани организма как у мужчин, так и у женщин, включая ткани молочных желез. У женщин повышенные сывороточные уровни ПСА описаны при ряде физиологических и патологических состояний, в том числе при доброкачественных заболеваниях молочной  железы и при раке молочной железы (РМЖ). ПСА рассматривают как потенциальный  серологический опухолеассоцированный маркер РМЖ, однако сведения о его возможной клинической значимости недостаточно убедительны.

Цель исследования – оценка уровней ПСА у женщин с РМЖ и оценка перспективности его изучения как диагностического показателя при начальных стадиях заболевания.

Материал и методы

Материал и методы. Сывороточные уровни ПСА измерены иммунохемилюминесцентным методом (aRcHitect, abbott) у 99 пациенток с гистологически верифицированным РМЖ  (карцинома in situ – 11, iА стадия – 56, iiА стадия – 32) и у 25 условно здоровых женщин-доноров.

Результаты

Результаты. В группе здоровых женщин ПСА был выявлен в 22/25 (88,0 %) образцах крови, среднее значение составило 4,0 ± 0,9 нг/л. В группе больных РМЖ  детектируемый уровень ПСА обнаружен в 68/99 (68,7 %) случаях, его средний уровень – 2,8 ± 0,9 нг/л. Отличия между группами больных РМЖ и доноров по среднему уровню маркера статистически недостоверны (p>0,05). Значения ПСА были выше у молодых женщин: у больных РМЖ моложе 40 лет доля ПСА-положительных случаев составила 89  %, у пациенток старше 50 лет – 60 %; в группах доноров моложе 40 лет и старше 50 лет – 100 % и 80 % соответственно. При карциноме in situ средний уровень ПСА оказался выше, чем при i и ii стадии заболевания (3,0 ± 1,2 нг/л против 1,9 ± 0,3 нг/л и 1,6 ± 0,3 нг/л соответственно; p>0,05). У больных РМЖ не выявлено зависимости концентраций ПСА от гистотипа, степени дифференцировки и молекулярного подтипа опухоли. 

Заключение

Заключение. Уровень ПСА не обладает клинической значимостью при ранних стадиях РМЖ, так как доля случаев с повышенным уровнем ПСА и среднее значение показателя у больных РМЖ на начальных этапах заболевания не отличаются от таковых в группе здоровых женщин.

Background

Background. Prostate-specific antigen (PSA ) is predominantly produced by prostate epithelium, however, other tissues can serve as its minor sources in both men and women, including breast tissue. In women, elevated serum PSA levels have been described in different physiological and pathological conditions, including benign breast diseases and breast cancer (BC). PSA is considered as a potential serum tumor marker for BC, but evidences of its possible clinical significance are insufficiently convincing.

Aim of the study

Aim of the study: investigation of PSA levels in female BC patients and assessment of perspectives of its study as a diagnostic tool for early detection of BC.

Material and methods

Material and methods. Serum PSA levels were measured by chemiluminescence immunoassay (ARCHITECT , Abbott) in 99 female patients with histologically confirmed BC (carcinoma in situ – 11, stage I – 56, stage IIA – 32) and 25 conditionally healthy female donors.

Results

Results. In the donor group, serum PSA was revealed in 22/25 (88,0 %) cases, and its mean level was 4.0 ± 0.9 ng/l. In the group of BC patients, detectable PSA level was revealed in 68/99 (68.7 %) cases, and its mean level was 2.8 ± 0.9 ng/l. Differences between groups of BC patients and donors in mean marker values were not statistically significant (p>0,05). Serum PSA levels were higher in young women: in the group of BC patients under 40 years old, percentage of PSA -positive cases was 89 %, in the group of patients over 50 years old – 60 %; in groups of donors under 40 and over 50 years old – 100 % and 80 %, respectively. In cases of in situ carcinoma, the mean serum PSA was higher than in cases with stages I and II (3.0 ± 1.2 ng/l vs 1.9 ± 0.3 ng/l and 1.6 ± 0.3 ng/l, respectively; p>0,05). In the group of BC patients, no PSA levels were found to be dependent on the histological type, grade and molecular subtype of the tumor.

Conclusion

Conclusion. The PSA level has no clinical significance in early stages of BC, since the proportion of cases with elevated PSA levels and it’s mean value in patients with early stages of BC don’t differ from those in the group of healthy women. 

простатический специфический антигенПСАрак молочной железыдиагностикаprostate-specific antigenPSAbreast cancerdiagnosticsReferencesKaprin A.D., Starinskiy V.V., Petrova G.V. Malignant neoplasms in Russia in 2018 (morbidity and mortality). Moscow, 2019. 250 p. (in Russian).Kaprin A.D., Starinskiy V.V., Petrova G.V. Malignant neoplasms in Russia in 2018 (morbidity and mortality). Moscow, 2019. 250 p. (in Russian).Сергеева Н.С., Скачкова Т.Е., Маршутина Н.В., Алексеев Б.Я., Каприн А.Д. Клиническая значимость ПСА-ассоциированных тестов в диагностике и стадировании рака предстательной железы. Онкология. Журнал им. П.А. Герцена. 2018; 7(1): 55–63. doi: 10.17116/onkolog20187155-67.Sergeeva N.S., Skachkova T.E., Marshutina N.V., Alekseev B.Ya., Kaprin A.D. Clinical significance of PSA-associated tests in the diagnosis and staging of prostate cancer. P.A. Herzen Journal of Oncology. 2018; 7(1): 55–63. (in Russian). doi: 10.17116/onkolog20187155-67.Yu H., Diamandis E.P., Levesque M., Giai M., Roagna R., Ponzone R., Sismondi P., Monne M., Croce C.M. Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Res Treat. 1996; 40(2): 171–8. doi: 10.1007/BF01806212.Yu H., Diamandis E.P., Levesque M., Giai M., Roagna R., Ponzone R., Sismondi P., Monne M., Croce C.M. Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Res Treat. 1996; 40(2): 171–8. doi: 10.1007/BF01806212.Yu H., Berkel H. Prostate-specific antigen (PSA) in women. J La State Med Soc. 1999 Apr; 151(4): 209–13.Yu H., Berkel H. Prostate-specific antigen (PSA) in women. J La State Med Soc. 1999 Apr; 151(4): 209–13.Olsson A.Y., Bjartell A., Lilja H., Lundwall A. Expression of prostatespecific antigen (PSA) and human glandular kallikrein 2 (hK2) in ileum and other extraprostatic tissues. Int J Cancer. 2005; 113(2): 290–7. doi: 10.1002/ijc.20605.Olsson A.Y., Bjartell A., Lilja H., Lundwall A. Expression of prostatespecific antigen (PSA) and human glandular kallikrein 2 (hK2) in ileum and other extraprostatic tissues. Int J Cancer. 2005; 113(2): 290–7. doi: 10.1002/ijc.20605.Nariţa D., Raica M., Anghel A., Suciu C., Cîmpean A. Immunohistochemical localization of prostate-specific antigen in benign and malignant breast conditions. Rom J Morphol Embryol. 2005; 46(1): 41–5.Nariţa D., Raica M., Anghel A., Suciu C., Cîmpean A. Immunohistochemical localization of prostate-specific antigen in benign and malignant breast conditions. Rom J Morphol Embryol. 2005; 46(1): 41–5.Kraus T.S., Cohen C., Siddiqui M.T. Prostate-specific antigen and hormone receptor expression in male and female breast carcinoma. Diagn Pathol. 2010 Sep 23; 5: 63. doi: 10.1186/1746-1596-5-63.Kraus T.S., Cohen C., Siddiqui M.T. Prostate-specific antigen and hormone receptor expression in male and female breast carcinoma. Diagn Pathol. 2010 Sep 23; 5: 63. doi: 10.1186/1746-1596-5-63.Mohajeri A., Zarghami N., Pourhasan Moghadam M., Alani B., Montazeri V., Baiat A., Fekhrjou A. Prostate-specific antigen gene expression and telomerase activity in breast cancer patients: possible relationship to steroid hormone receptors. Oncol Res. 2011; 19(8–9): 375–80. doi: 10.3727/096504011x13123323849636.Mohajeri A., Zarghami N., Pourhasan Moghadam M., Alani B., Montazeri V., Baiat A., Fekhrjou A. Prostate-specific antigen gene expression and telomerase activity in breast cancer patients: possible relationship to steroid hormone receptors. Oncol Res. 2011; 19(8–9): 375–80. doi: 10.3727/096504011x13123323849636.Zarghami N., Grass L., Sauter E.R., Diamandis E.P. Prostatespecific antigen in serum during the menstrual cycle. Clin Chem. 1997 Oct; 43(10): 1862–7.Zarghami N., Grass L., Sauter E.R., Diamandis E.P. Prostatespecific antigen in serum during the menstrual cycle. Clin Chem. 1997 Oct; 43(10): 1862–7.Romppanen J., Keskikuru R., Kataja V., Eskelinen M., Kosma V.M., Savolainen K., Uusitupa M., Mononen I. Measurement of prostate-specific antigen in detection of benign or malignant breast disease in women. Br J Cancer. 1999 Mar; 79(9–10): 15837. doi: 10.1038/sj.bjc.6690252.Romppanen J., Keskikuru R., Kataja V., Eskelinen M., Kosma V.M., Savolainen K., Uusitupa M., Mononen I. Measurement of prostate-specific antigen in detection of benign or malignant breast disease in women. Br J Cancer. 1999 Mar; 79(9–10): 15837. doi: 10.1038/sj.bjc.6690252.Black M.H., Giai M., Ponzone R., Sismondi P., Yu H, Diamandis E.P. Serum total and free prostate-specific antigen for breast cancer diagnosis in women. Clin Cancer Res. 2000 Feb; 6(2): 467–73.Black M.H., Giai M., Ponzone R., Sismondi P., Yu H, Diamandis E.P. Serum total and free prostate-specific antigen for breast cancer diagnosis in women. Clin Cancer Res. 2000 Feb; 6(2): 467–73.Dash P., Pati S., Mangaraj M., Sahu P.K., Mohapatra P.C. Serum total PSA and free PSA in breast tumors. Indian J Clin Biochem. 2011 Apr; 26(2): 182–6. doi: 10.1007/s12291-011-0115-5.Dash P., Pati S., Mangaraj M., Sahu P.K., Mohapatra P.C. Serum total PSA and free PSA in breast tumors. Indian J Clin Biochem. 2011 Apr; 26(2): 182–6. doi: 10.1007/s12291-011-0115-5.Das S., Paul R., De U., Mukhopadhyay M. The lady with raised prostate specific antigen: do we need to worry? Asian Pac J Cancer Prev. 2011; 12(8): 2051–3.Das S., Paul R., De U., Mukhopadhyay M. The lady with raised prostate specific antigen: do we need to worry? Asian Pac J Cancer Prev. 2011; 12(8): 2051–3.Mashkoor F.C., Al-Asadi J.N., Al-Naama L.M. Serum level of prostate-specific antigen (PSA) in women with breast cancer. Cancer Epidemiol. 2013 Oct; 37(5): 613–8. doi: 10.1016/j.canep.2013.06.009.Mashkoor F.C., Al-Asadi J.N., Al-Naama L.M. Serum level of prostate-specific antigen (PSA) in women with breast cancer. Cancer Epidemiol. 2013 Oct; 37(5): 613–8. doi: 10.1016/j.canep.2013.06.009.Razavi S.H., Ghajarzadeh M., Abdollahi A., Shoar S., Omranipour R. Is Serum Prostate-specific Antigen a Diagnostic Marker for Benign and Malignant Breast Tumors in Women? Int J Prev Med. 2015; 6: 15. doi: 10.4103/2008-7802.151824.Razavi S.H., Ghajarzadeh M., Abdollahi A., Shoar S., Omranipour R. Is Serum Prostate-specific Antigen a Diagnostic Marker for Benign and Malignant Breast Tumors in Women? Int J Prev Med. 2015; 6: 15. doi: 10.4103/2008-7802.151824.Jahir E.T., Devi R., Borthakur B.B. Study of Serum Total PSA and Free PSA as an Oncological Marker in Breast Tumour. J Clin Diagn Res. 2017 Mar; 11(3): BC13-BC16. doi: 10.7860/JCDR/2017/22111.9543.Jahir E.T., Devi R., Borthakur B.B. Study of Serum Total PSA and Free PSA as an Oncological Marker in Breast Tumour. J Clin Diagn Res. 2017 Mar; 11(3): BC13-BC16. doi: 10.7860/JCDR/2017/22111.9543.Yu H., Giai M., Diamandis E.P., Katsaros D., Sutherland D.J., Levesque M.A., Roagna R., Ponzone R., Sismondi P. Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res. 1995 May 15; 55(10): 2104–10.Yu H., Giai M., Diamandis E.P., Katsaros D., Sutherland D.J., Levesque M.A., Roagna R., Ponzone R., Sismondi P. Prostate-specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res. 1995 May 15; 55(10): 2104–10.Borchert G.H., Melegos D.N., Tomlinson G., Giai M., Roagna R., Ponzone R., Sgro L., Diamandis E.P. Molecular forms of prostate-specific antigen in the serum of women with benign and malignant breast diseases. Br J Cancer. 1997; 76(8): 1087–94. doi: 10.1038/bjc.1997.512.Borchert G.H., Melegos D.N., Tomlinson G., Giai M., Roagna R., Ponzone R., Sgro L., Diamandis E.P. Molecular forms of prostate-specific antigen in the serum of women with benign and malignant breast diseases. Br J Cancer. 1997; 76(8): 1087–94. doi: 10.1038/bjc.1997.512.Clendenen T.V., Ge W., Koenig K.L., Afanasyeva Y., Agnoli C., Brinton L.A., Darvishian F., Dorgan J.F., Eliassen A.H., Falk R.T., Hallmans G., Hankinson S.E., Hoffman-Bolton J., Key T.J., Krogh V., Nichols H.B., Sandler D.P., Schoemaker M.J., Sluss P.M., Sund M., Werdlow A.J., Visvanathan K., Zeleniuch-Jacquotte A., Liu M. Breast cancer risk prediction in women aged 35-50 years: impact of including sex hormone concentrations in the Gail model. Breast Cancer Res. 2019 Mar; 21(1): 42. doi: 10.1186/s13058-019-1126-z.Clendenen T.V., Ge W., Koenig K.L., Afanasyeva Y., Agnoli C., Brinton L.A., Darvishian F., Dorgan J.F., Eliassen A.H., Falk R.T., Hallmans G., Hankinson S.E., Hoffman-Bolton J., Key T.J., Krogh V., Nichols H.B., Sandler D.P., Schoemaker M.J., Sluss P.M., Sund M., Werdlow A.J., Visvanathan K., Zeleniuch-Jacquotte A., Liu M. Breast cancer risk prediction in women aged 35-50 years: impact of including sex hormone concentrations in the Gail model. Breast Cancer Res. 2019 Mar; 21(1): 42. doi: 10.1186/s13058-019-1126-z.Hüsing A., Fortner R.T., Kühn T., Overvad K., Tjønneland A., Olsen A., Boutron-Ruault M.C., Severi G., Fournier A., Boeing H., Trichopoulou A., Benetou V., Orfanos P., Masala G., Pala V., Tumino R., Fasanelli F., Panico S., Bueno de Mesquita H.B., Peeters P.H., van Gills C.H., Quirós J.R., Agudo A., Sánchez M.J., Chirlaque M.D., Barricarte A., Amiano P., Khaw K.T., Travis R.C., Dossus L., Li K., Ferrari P., Merritt M.A., Tzoulaki I., Riboli E., Kaaks R.Added Value of Serum Hormone Measurements in Risk Prediction Models for Breast Cancer for Women Not Using Exogenous Hormones: Results from the EPIC Cohort. Clin Cancer Res. 2017; 23(15): 4181–4189. doi: 10.1158/1078-0432.CCR-16-3011.Hüsing A., Fortner R.T., Kühn T., Overvad K., Tjønneland A., Olsen A., Boutron-Ruault M.C., Severi G., Fournier A., Boeing H., Trichopoulou A., Benetou V., Orfanos P., Masala G., Pala V., Tumino R., Fasanelli F., Panico S., Bueno de Mesquita H.B., Peeters P.H., van Gills C.H., Quirós J.R., Agudo A., Sánchez M.J., Chirlaque M.D., Barricarte A., Amiano P., Khaw K.T., Travis R.C., Dossus L., Li K., Ferrari P., Merritt M.A., Tzoulaki I., Riboli E., Kaaks R.Added Value of Serum Hormone Measurements in Risk Prediction Models for Breast Cancer for Women Not Using Exogenous Hormones: Results from the EPIC Cohort. Clin Cancer Res. 2017; 23(15): 4181–4189. doi: 10.1158/1078-0432.CCR-16-3011.Kaaks R., Tikk K., Sookthai D., Schock H., Johnson T., Tjønneland A., Olsen A., Overvad K., Clavel-Chapelon F., Dossus L., Baglietto L., Rinaldi S., Chajes V., Romieu I., Boeing H., Schütze M., Trichopoulou A., Lagiou P., Trichopoulos D., Palli D., Sieri S., Tumino R., Ricceri F., Mattiello A., Buckland G., Ramón Quirós J., Sánchez M.J., Amiano P., Chirlaque M.D., Barricarte A., Bas Bueno-de-Mesquita H., van Gils C.H., Peeters P.H., Andersson A., Sund M., Weiderpass E., Khaw K.T., Wareham N., Key T.J., Travis R.C., Merritt M.A., Gunter M.J., Riboli E., Lukanova A. Premenopausal serum sex hormone levels in relation to breast cancer risk, overall and by hormone receptor status - results from the EPIC cohort. Int J Cancer. 2014; 134(8): 1947–57. doi: 10.1002/ijc.28528.Kaaks R., Tikk K., Sookthai D., Schock H., Johnson T., Tjønneland A., Olsen A., Overvad K., Clavel-Chapelon F., Dossus L., Baglietto L., Rinaldi S., Chajes V., Romieu I., Boeing H., Schütze M., Trichopoulou A., Lagiou P., Trichopoulos D., Palli D., Sieri S., Tumino R., Ricceri F., Mattiello A., Buckland G., Ramón Quirós J., Sánchez M.J., Amiano P., Chirlaque M.D., Barricarte A., Bas Bueno-de-Mesquita H., van Gils C.H., Peeters P.H., Andersson A., Sund M., Weiderpass E., Khaw K.T., Wareham N., Key T.J., Travis R.C., Merritt M.A., Gunter M.J., Riboli E., Lukanova A. Premenopausal serum sex hormone levels in relation to breast cancer risk, overall and by hormone receptor status - results from the EPIC cohort. Int J Cancer. 2014; 134(8): 1947–57. doi: 10.1002/ijc.28528.Zarghami N,, Grass L,, Diamandis E,P. Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer. Br J Cancer. 1997; 75(4): 579–88. doi: 10.1038/bjc.1997.101.Zarghami N,, Grass L,, Diamandis E,P. Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer. Br J Cancer. 1997; 75(4): 579–88. doi: 10.1038/bjc.1997.101.Guay A., Munarriz R., Jacobson J., Talakoub L., Traish A., Quirk F., Goldstein I., Spark R. Serum androgen levels in healthy premenopausal women with and without sexual dysfunction: Part A. Serum androgen levels in women aged 20-49 years with no complaints of sexual dysfunction. Int J Impot Res. 2004 Apr; 16(2): 112–20. doi: 10.1038/sj.ijir.3901178.Guay A., Munarriz R., Jacobson J., Talakoub L., Traish A., Quirk F., Goldstein I., Spark R. Serum androgen levels in healthy premenopausal women with and without sexual dysfunction: Part A. Serum androgen levels in women aged 20-49 years with no complaints of sexual dysfunction. Int J Impot Res. 2004 Apr; 16(2): 112–20. doi: 10.1038/sj.ijir.3901178.Kim J., Coetzee G.A. Prostate specific antigen gene regulation by androgen receptor. J Cell Biochem. 2004 Oct 1; 93(2): 233–41. doi: 10.1002/jcb.20228.Kim J., Coetzee G.A. Prostate specific antigen gene regulation by androgen receptor. J Cell Biochem. 2004 Oct 1; 93(2): 233–41. doi: 10.1002/jcb.20228.Majumder A., Singh M., Tyagi S.C. Post-menopausal breast cancer: from estrogen to androgen receptor. Oncotarget. 2017 Oct 27; 8(60): 102739–758. doi: 10.18632/oncotarget.22156.Majumder A., Singh M., Tyagi S.C. Post-menopausal breast cancer: from estrogen to androgen receptor. Oncotarget. 2017 Oct 27; 8(60): 102739–758. doi: 10.18632/oncotarget.22156.Седаков И.Е., Рогалев А.В., Садрицкая Я.В., Стеценко И.Н. Андрогены и рак молочной железы: что мы знаем? Новообразование. 2019; 11(2): 63–7. doi: 10.26435/neoplasm.v11i2.276.Sedakov I.E., Rogalev A.V., Sadritskaya Ya.V., Stetsenko I.N. Androgens and breast cancer: what do we know? Neoplasm. 2019; 11(2): 63–7. (in Russian). doi: 10.26435/neoplasm.v11i2.276.Gerratana L., Basile D., Buono G., De Placido S., Giuliano M., Minichillo S., Coinu A., Martorana F., De Santo I., Del Mastro L., De Laurentiis M., Puglisi F., Arpino G. Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype. Cancer Treat Rev. 2018 Jul; 68: 102–110. doi: 10.1016/j.ctrv.2018.06.005.Gerratana L., Basile D., Buono G., De Placido S., Giuliano M., Minichillo S., Coinu A., Martorana F., De Santo I., Del Mastro L., De Laurentiis M., Puglisi F., Arpino G. Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype. Cancer Treat Rev. 2018 Jul; 68: 102–110. doi: 10.1016/j.ctrv.2018.06.005.Hanamura T., Ohno K., Hokibara S., Murasawa H., Nakamura T., Watanabe H., Kaizuka M., Sawano S., Koyama H., Ito K.I. Clinical significance of serum PSA in breast cancer patients. BMC Cancer. 2019 Oct 29; 19(1): 1021. doi: 10.1186/s12885-019-6256-2.Hanamura T., Ohno K., Hokibara S., Murasawa H., Nakamura T., Watanabe H., Kaizuka M., Sawano S., Koyama H., Ito K.I. Clinical significance of serum PSA in breast cancer patients. BMC Cancer. 2019 Oct 29; 19(1): 1021. doi: 10.1186/s12885-019-6256-2.Giai M., Yu H., Roagna R., Ponzone R., Katsaros D., Levesque M.A., Diamandis E.P. Prostate-specific antigen in serum of women with breast cancer. Br J Cancer. 1995 Sep; 72(3): 728–31. doi: 10.1038/bjc.1995.401.Giai M., Yu H., Roagna R., Ponzone R., Katsaros D., Levesque M.A., Diamandis E.P. Prostate-specific antigen in serum of women with breast cancer. Br J Cancer. 1995 Sep; 72(3): 728–31. doi: 10.1038/bjc.1995.401.Radowicki S., Kunicki M., Bandurska-Stankiewicz E. Prostatespecific antigen in the serum of women with benign breast disease. Eur J Obstet Gynecol Reprod Biol. 2008 Jun; 138(2): 212–6. doi: 10.1016/j.ejogrb.2007.05.023.Radowicki S., Kunicki M., Bandurska-Stankiewicz E. Prostatespecific antigen in the serum of women with benign breast disease. Eur J Obstet Gynecol Reprod Biol. 2008 Jun; 138(2): 212–6. doi: 10.1016/j.ejogrb.2007.05.023.

The authors declare that there are no conflicts of interest present.